<DOC>
	<DOCNO>NCT02667535</DOCNO>
	<brief_summary>This Phase I trial evaluate Pharmacokinetics , Pharmacodynamics Safety Isosorbide Mononitrate gel usage participant anal fissure healthy volunteer . Three dos use patient anal fissure ( 0.5 % , 1.0 % 2.0 % ) healthy volunteer receive 2.0 % dose . All treatment last 7 day .</brief_summary>
	<brief_title>PK , PD Safety Comparative Trial Isosorbide Mononitrate Gel Healthy Participants With Anal Fissure</brief_title>
	<detailed_description>This Phase I , open-label , parallel trial evaluate Pharmacokinetics , Pharmacodynamics Safety Isosorbide Mononitrate gel usage participant anal fissure healthy volunteer . Investigational product randomly assign follow : - healthy volunteer receive 2g ( 2.0 % ) investigational product single dose , undergo washout period 7 day ; subsequently , receive 2g investigational product daily , 7 consecutive day ; - participant anal fissure receive 2g investigational product , either 0.5 % , 1.0 % 2.0 % , single dose , undergo washout period 7 day ; subsequently , receive 2g investigational product , either 0.5 % , 1.0 % 2.0 % , daily , 7 consecutive day .</detailed_description>
	<mesh_term>Fissure Ano</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>Male female subject age ≥ 18 yearsold ; Body mass index ( BMI ) ≥ 19 Kg/m2 ≤ 35 Kg/m2 ; For healthy volunteer : good health condition without significant disease , accord best medical judgement , accord protocol requirement study evaluation : medical history , blood pressure heart rate measurement , physical examination , electrocardiogram ( ECG ) screen laboratory test ; For participant condition study : anal fissure ; Ability understand nature objective trial , include risk adverse event ; willingness cooperate researcher proceed accord study requirement , shall confirm Informed Consent Form signature . Known hypersensitivity investigational product ( naproxen rebamipide ) chemically related compound ; history serious adverse reaction hypersensitivity drug ; Chronic therapy drug , except oral contraceptive medication authorize principal investigator ( case individually evaluate ) ; History hepatic , kidney , lung , gastrointestinal , epileptic , hematologic psychiatric disease ; hypotension hypertension , comorbidity require priority immediate treatment ot , principal investigator discretion , might interfere study participation expose study participant risk predict ; Deviations screen laboratory result consider clinically relevant principal investigator ; Smoking ; History drug alcohol addiction excessive alcohol consumption ( &gt; 35 g/ day ) ; Use regular medication within 2 week prior study enrollment use medication within one week prior study enrollment , except oral contraceptive case , base drug 's metabolite 's halflife , complete elimination assume ; Treatment , within 6 month trial , drug know well establish toxic potential major organ ; Participation experimental research administration experimental drug within six month trial ; Donation loss 450 mL blood ( ) within 3 month trial , 4 donation within 12 month trial ; Any condition , accord investigator 's best judgement , prevents subject participate trial ; Pregnancy , labor miscarriage 12 week admission predict date .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>